Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Eaton Corporation plc (ETN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Eaton Corporation plc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while Eaton Corporation plc trades at $458.9 (market cap $172.82B). The key difference: Eaton Corporation plc is far larger — about 34.1× ACADIA Pharmaceuticals Inc.'s market cap, and Eaton Corporation plc pays a 0.99% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ETN | |
|---|---|---|
Market Cap | $5.07B | $172.82B |
Sector | Health | Technology |
52-Week High | $29.41 | $459.29 |
52-Week Low | $20.06 | $315.82 |
Enterprise Value | $4.19B | $193.45B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.47, up 0.26% with strong technical momentum and bullish moving average signals. The company reported robust Q2 2026 earnings of $0.18 per share, beating estimates by 164%, driven by strong Daybue and Nuplazid sales. Revenue reached $1.07 billion in 2025 with impressive net income margins of 33.42%. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
ACAD presents compelling growth potential with 70% analyst buy ratings and a $33.89 consensus price target implying 15% upside. Strong revenue growth trajectory and expanding profitability support bullish case, though elevated EV/EBITDA of 42.55 and recent RSI overbought signals warrant caution. Key risk remains clinical trial outcomes for pipeline assets.
Eaton Corporation (ETN) trades at $459.96, up 3.37% with strong technical momentum and bullish moving average signals. The company delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.15 beating expectations of $3.07. Revenue growth continues with 2026 projections at $30.0 billion, though net profit margin is expected to compress to 12.75%. Recent news highlights Eaton's $7 million Air Force contract for quantum computing grid security and strong AI infrastructure demand.
Outlook remains positive with analyst consensus price target of $499.75 (8.6% upside) and unanimous bullish ratings (26 Buy, 0 Sell). Key risks include premium valuation (P/E 45.31) and execution challenges in meeting raised 2026 guidance. The stock's proximity to 52-week highs suggests near-term consolidation potential despite strong fundamental momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →
